Effect of dietary omega-3 fatty acids on castrate-resistant prostate cancer and tumor-associated macrophages.
Animals
Biomarkers
Chemotaxis, Leukocyte
/ drug effects
Dietary Fats
/ administration & dosage
Disease Progression
Fatty Acids, Omega-3
/ administration & dosage
Humans
Immunophenotyping
Lymphocytes, Tumor-Infiltrating
/ immunology
Macrophages
/ drug effects
Male
Mice
Models, Biological
Prostatic Neoplasms, Castration-Resistant
/ genetics
RNA, Messenger
/ genetics
Tumor Microenvironment
/ drug effects
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
17
05
2019
accepted:
22
07
2019
revised:
01
07
2019
pubmed:
24
8
2019
medline:
24
9
2020
entrez:
24
8
2019
Statut:
ppublish
Résumé
M2-like macrophages are associated with the pathogenesis of castrate-resistant prostate cancer (CRPC). We sought to determine if dietary omega-3 fatty acids (ω-3 FAs) delay the development and progression of CRPC and inhibit tumor-associated M2-like macrophages. MycCap cells were grown subcutaneously in immunocompetent FVB mice. Mice were castrated when tumors reached 300 mm The ω-3 diet combined with castration lead to greater MycCap tumor regression (tumor volume reduction: 182.2 ± 33.6 mm Dietary omega-3 FAs (as compared to omega-6 FAs) decreased the development and progression of CRPC in an immunocompetent mouse model, and had inhibitory effects on M2-like macrophage function. Clinical trials are warranted evaluating if a fish oil-based diet can delay the time to castration resistance in men on androgen deprivation therapy, whereas further preclinical studies are warranted evaluating fish oil for more advanced CRPC.
Sections du résumé
BACKGROUND
M2-like macrophages are associated with the pathogenesis of castrate-resistant prostate cancer (CRPC). We sought to determine if dietary omega-3 fatty acids (ω-3 FAs) delay the development and progression of CRPC and inhibit tumor-associated M2-like macrophages.
METHODS
MycCap cells were grown subcutaneously in immunocompetent FVB mice. Mice were castrated when tumors reached 300 mm
RESULTS
The ω-3 diet combined with castration lead to greater MycCap tumor regression (tumor volume reduction: 182.2 ± 33.6 mm
CONCLUSIONS
Dietary omega-3 FAs (as compared to omega-6 FAs) decreased the development and progression of CRPC in an immunocompetent mouse model, and had inhibitory effects on M2-like macrophage function. Clinical trials are warranted evaluating if a fish oil-based diet can delay the time to castration resistance in men on androgen deprivation therapy, whereas further preclinical studies are warranted evaluating fish oil for more advanced CRPC.
Identifiants
pubmed: 31439889
doi: 10.1038/s41391-019-0168-8
pii: 10.1038/s41391-019-0168-8
pmc: PMC7031053
mid: NIHMS1535498
doi:
Substances chimiques
Biomarkers
0
Dietary Fats
0
Fatty Acids, Omega-3
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
127-135Subventions
Organisme : NIH HHS
ID : RO1CA231219
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092131
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG055369
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231219
Pays : United States
Références
Augustsson K, Michaud DS, Rimm EB, Leitzmann MF, Stampfer MJ, Willett WC, et al. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:64–67.
pubmed: 12540506
Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013;105:1132–41.
doi: 10.1093/jnci/djt174
Brasky TM, Till C, White E, Neuhouser ML, Song X, Goodman P, et al. Serum phospholipid fatty acids and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2011;173:1429–39.
doi: 10.1093/aje/kwr027
Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, et al. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr. 2004;80:204–16.
doi: 10.1093/ajcn/80.1.204
Lovegrove C, Ahmed K, Challacombe B, Khan MS, Popert R, Dasgupta P. Systematic review of prostate cancer risk and association with consumption of fish and fish-oils: analysis of 495,321 participants. Int J Clin Pract. 2015;69:87–105.
doi: 10.1111/ijcp.12514
Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer. 1999;81:1238–42.
doi: 10.1038/sj.bjc.6690835
Friedrichs W, Ruparel SB, Marciniak RA, deGraffenried L. Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. Nutr Cancer. 2011;63:771–7.
doi: 10.1080/01635581.2011.570892
Lloyd JC, Masko EM, Wu C, Keenan MM, Pilla DM, Aronson WJ, et al. Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression. Prostate Cancer Prostatic Dis. 2013;16:285–91.
doi: 10.1038/pcan.2013.19
Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, et al. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis. 2012;33:404–12.
doi: 10.1093/carcin/bgr290
Gevariya N, Besancon M, Robitaille K, Picard V, Diabate L, Alesawi A, et al. Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice. Prostate. 2019;79:9–20.
doi: 10.1002/pros.23706
Liang P, Henning SM, Schokrpur S, Wu L, Doan N, Said J, et al. Effect of ietary omega-3 fatty acids on tumor-associated macrophages and prostate cancer progression. Prostate. 2016;76:1293–302.
doi: 10.1002/pros.23218
Lundholm M, Hagglof C, Wikberg ML, Stattin P, Egevad L, Bergh A, et al. Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions. Sci Rep. 2015;5:15651.
doi: 10.1038/srep15651
Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, Baroni G, et al. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2014;33:2423–31.
doi: 10.1038/onc.2013.191
Lanciotti M, Masieri L, Raspollini MR, Minervini A, Mari A, Comito G, et al. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. BioMed Res Int. 2014;2014:486798.
doi: 10.1155/2014/486798
Zarif JC, Taichman RS, Pienta KJ. TAM macrophages promote growth and metastasis within the cancer ecosystem. Oncoimmunology. 2014;3:e941734.
doi: 10.4161/21624011.2014.941734
Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460.
doi: 10.1155/2015/816460
Silva JAF, Bruni-Cardoso A, Augusto TM, Damas-Souza DM, Barbosa GO, Felisbino SL, et al. Macrophage roles in the clearance of apoptotic cells and control of inflammation in the prostate gland after castration. Prostate. 2018;78:95–103.
doi: 10.1002/pros.23449
Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res. 2015;75:950–62.
doi: 10.1158/0008-5472.CAN-14-0992
Zarif JC, Yang W, Hernandez JR, Zhang H, Pienta KJ. The identification of macrophage-enriched glycoproteins using glycoproteomics. Mol Cell Proteom. 2017;16:1029–37.
doi: 10.1074/mcp.M116.064444
Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 2003;4:223–38.
doi: 10.1016/S1535-6108(03)00197-1
Watson CS, Bialek P, Anzo M, Khosravi J, Yee SP, Han VK. Elevated circulating insulin-like growth factor binding protein-1 is sufficient to cause fetal growth restriction. Endocrinology. 2006;147:1175–86.
doi: 10.1210/en.2005-0606
Zhang C, Wang Y, Wang F, Wang Z, Lu Y, Xu Y, et al. Quantitative profiling of glycerophospholipids during mouse and human macrophage differentiation using targeted mass spectrometry. Sci Rep. 2017;7:412.
doi: 10.1038/s41598-017-00341-2
Liang P, Henning SM, Guan J, Grogan T, Elashoff D, Olefsky JM, et al. Role of host GPR120 in mediating dietary omega-3 fatty acid inhibition of prostate cancer. J Natl Cancer Inst. 2019;111:52–59.
doi: 10.1093/jnci/djy125
Ngo TH, Barnard RJ, Anton T, Tran C, Elashoff D, Heber D, et al. Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. Cancer Res. 2004;64:1252–4.
doi: 10.1158/0008-5472.CAN-03-3830
Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, et al. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res. 2003;9:2734–43.
pubmed: 12855654
Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019;75:285–93.
doi: 10.1016/j.eururo.2018.07.035
Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464:302–5.
doi: 10.1038/nature08782
Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013;4:e764.
doi: 10.1038/cddis.2013.270
Ren X, Fu X, Zhang X, Chen S, Huang S, Yao L, et al. Testosterone regulates 3T3-L1 pre-adipocyte differentiation and epididymal fat accumulation in mice through modulating macrophage polarization. Biochem Pharmacol. 2017;140:73–88.
doi: 10.1016/j.bcp.2017.05.022
Zhang P, Zhao S, Wu C, Li J, Li Z, Wen C, et al. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages. Immunotherapy. 2018;10:935–49.
doi: 10.2217/imt-2018-0012
Berquin IM, Edwards IJ, Kridel SJ, Chen YQ. Polyunsaturated fatty acid metabolism in prostate cancer. Cancer Metast Rev. 2011;30:295–309.
doi: 10.1007/s10555-011-9299-7
Aucoin M, Cooley K, Knee C, Fritz H, Balneaves LG, Breau R, et al. Fish-derived omega-3 fatty acids and prostate cancer: a systematic review. Integr Cancer Ther. 2017;16:32–62.
doi: 10.1177/1534735416656052
Gu Z, Wu J, Wang S, Suburu J, Chen H, Thomas MJ, et al. Polyunsaturated fatty acids affect the localization and signaling of PIP3/AKT in prostate cancer cells. Carcinogenesis. 2013;34:1968–75.
doi: 10.1093/carcin/bgt147